Recruiting

Phase 1

Phase 2

NEO212Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Sponsor:

Neonc Technologies, Inc.

Code:

NCT06047379

Conditions

Diffuse Astrocytoma, IDH-Mutant

Glioblastoma, IDH-wildtype

Brain Metastases, Adult

Cervical Cancer

Colorectal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NEO212 Oral Capsule

Ipilimumab

Pembrolizumab

Nivolumab

Regorafenib

Study Details

Brief summary:

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain.

The study will have three phases, Phase 1, Phase 2a and Phase 2b.

Conditions

Diffuse Astrocytoma, IDH-Mutant

Glioblastoma, IDH-wildtype

Brain Metastases, Adult

Cervical Cancer

Colorectal Cancer

Study ID

NCT06047379

Start date

Nov 1, 2023

Status verified date

Jul, 2026

Completion date

Aug 31, 2027

Anticipated

Primary completion date

Feb 28, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Patient must be ≥ 18yrs of age.
Patient must have the ability to understand, and the willingness to sign, a written informed consent form.
Patient has been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
Any toxicity from prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.
If progression of disease occurs within 90 days or conformal radiation, the progression/recurrence must be outside of the radiation field or proven by biopsy/resection.
Patient with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype must have a Karnofsky Performance Status (KPS) of ≥ 60.
Patient with select solid tumors must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Patient must have an expected survival or at least three months.
Patient must have a baseline MRI of the brain with gadolinium within 14 days of administration of NEO212.
Patient with select solid tumors must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212.
Patients must be able to comply with all study assessments.
If patient suffers from seizures (s)he must be controlled on a stable dose of anti-epileptics for 14-days prior to the date of informed consent.
Patient must have adequate organ and marrow function as follows:

Absolute neutrophil count ≥ 1,500/microliter
Platelets ≥ 100,000/microliter
Total bilirubin within normal institutional limits
AST (SGOT) / ALT (SPGT) ≤ 2.5 x institutional upper limit of normal
Creatinine clearance (CrCl) of >60 mL/min (using the Cockcroft-Gault formula or 24- hour urine collection).
Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.

A female of child-bearing potential is any women (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

Has not undergone a hysterectomy or bilateral oophorectomy; or
Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months).
A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212.
A serum pregnancy test will be repeated immediately if pregnancy is suspected.

Phase 1: (dose escalation)

Patient must:

have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
Patients receiving prior systemic therapy must have a minimum wash-out period (defined as the period prior to receipt of the first dose of NEO212) of:

28 days or 5 half-lives (whichever is shorter) elapsed from the administration from any experimental agent;
2 weeks from administration of immunotherapies;
28 days from administration of cytotoxic agents; and
7 days from administration of non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid, and herbal medicine).

NOTE: No washout is necessary for alternating electrical fields.

Phase 2a: (safety run-in)

Patient must have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria.
Patient must have measurable/evaluable systemic disease per RECIST v1.1 criteria.

Phase 2b: (efficacy)

Patient must:

have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria
Patient with select solid tumors must have measurable/evaluable systemic disease per RECIST v1.1 criteria.
Creatinine clearance (CrCl) of >60 mL/min (using the Cockcroft-Gault formula or 24-hour urine collection). Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.

Exclusion Criteria: (all Phases)

Patient in Phase 1 concurrently receiving any other antitumor therapy.
Patient in Phase 2a or 2b who is concurrently receiving any SOC therapy not listed in Appendix 1.
Patients with metastases to the spinal cord parenchyma.
Patients with metastases to the meninges.
Patient has received stereotactic or highly conformal radiotherapy to CNS lesions within 2 weeks before receipt of NEO212.
Patient with history of known leptomeningeal involvement.
Patient has prior history or new diagnosis of secondary cancer within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin.
Patient has a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470 msec, a history of additional risk factors for TdP (e.g. heart failure, hypokalemia), and/or the use of concomitant medications that prolong QT/QTc interval.
Patient had surgery within 7 days prior to the date of informed consent.
Patient has not recovered to Grade 1 from treatment related adverse events due to chemotherapy, immunotherapy, or radiation therapy.
Patient had prior treatment with perillyl alcohol.
Patient has a history of allergic reactions attributed to perillyl alcohol.
Patients in Phase 2b with Astrocytoma IDH-mutant, or Glioblastoma IDH-wildtype who have had more than one recurrence or progression of his/her primary CNS tumor(s).

Study Design

Enrollment

134 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Phase 2a Safety Run-In - NEO212 and Ipilimumab

\- Unresectable or metastatic melanoma with uncontrolled metastases to the brain.

NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.

Ipilimumab - 3 mg/kg administered IV over 90 minutes every 3 weeks for a maximum of 3 doses per package insert.

experimental: Phase 2a Safety Run-In - NEO212 and Pembrolizumab

The following primary cancers with uncontrolled metrastases to the brain:

Unresectable or metastatic melanoma.
NSCLC expressing PD-L1, with no EGFR or ALK genomic tumor aberrations.
Metastatic NSCLC whose tumors express PD-L1.
EGFR or ALK genomic tumor aberrations must have disease progression.
SCLC.
Unresectable, recurrent HNSCC whose tumors express PD-L1.
HNSCC on or after platinum-containing chemotherapy.
Urothelial carcinoma whose tumors express PD-L1.
Urothelial carcinoma.
Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
Microsatellite Instability-high or Mismatch Repair Deficient Colorectal Cancer (CRC).
Gastric or gastroesophageal junction adenocarcinoma.
Esophageal or gastroesophageal juncUon (GEJ).
Cervical cancer.
Merkel cell carcinoma.

NEO212 - Same as Arm 1.

Pembrolizumab - 200 mg administered every 3 weeks per package insert.

experimental: Phase 2a Safety Run-In - NEO212 and Nivolumab

The following primary cancers with uncontrolled metrastases to the brain:

Unresectable or metastatic melanoma.
Metastatic non-small cell lung cancer.
Advanced renal cell carcinoma.
Squamous cell carcinoma of the head and neck.
Urothelial carcinoma.
Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Unresectable esophageal squamous cell carcinoma (ESCC).

NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.

Nivolumab - 240 mg administered every 2 weeks per package insert

experimental: Phase 2a Safety Run-In - NEO212 and Stivarga (Regorafenib)

\- Colorectal cancer (CRC) with uncontrolled metastases to the brain who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anU-EGFR therapy.

NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.

Stivarga - 160 mg orally, once daily for the first 21 days of each 28-day cycle per package insert

experimental: Phase 2a Safety Run-In - NEO212 and CarbolaUn (ParaplaUn) + Paclitaxel (Taxol)

\- Colorectal cancer (CRC) with uncontrolled metastases to the brain.

NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.

Carboplatin - 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles per package insert.

Paclitaxel - 135mg/m2 IV administered over 24 hours, every 3 weeks per package insert.

experimental: Phase 2a Safety Run-In - NEO212 and FOLFIRI (Zaltrap) + Bevacizumab (Avastin)

\- Metastatic colorectal cancer (mCRC) with uncontrolled metastases to the brain, that is resistant to or has progressed following an oxaliplatin-containing regimen

NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.

FOLFIRI - 4 mg/kg aIV over 1 hour every 2 weeks.

Bevacizumab - 10 mg/kg IV every 2 weeks.

experimental: Phase 2b efficacy - NEO212 for Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype

Patients receiving NEO212 alone for treatment of Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype.

NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.

experimental: Phase 2b efficacy - NEO212 & SOC for Uncontrolled Metastases to the Brain

Patients receiving NEO212 in combination with select standard of care treatments for treatment of uncontrolled metastases to the brain.

NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.

SOC treatments established to be safe in Phase 2a of the study will be used in this arm of Phase 2b.

Interventions

NEO212 Oral Capsule

NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).

Ipilimumab

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.

Pembrolizumab

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.

Nivolumab

Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.

Regorafenib

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition

Carboplatin

Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.

Paclitaxel

Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection

FOLFIRI Protocol

FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:

FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.

Bevacizumab

Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma

Primary outcome measure

Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain [ Time Frame: 6 months ]
Phase 1: Identify the maximum tolerated dose (MTD) of NEO212 [ Time Frame: 6 months ]
Phase 1: Determine the recommended Phase 2 dose (RP2D) of NEO212 [ Time Frame: 6 months ]
Phase 2a: Assess the safety and tolerability of orally administered NEO212 in combination with select SOC regimens following a standard 3+3 design in patients with select solid tumors with uncontrolled metastases to the brain [ Time Frame: 6 months ]
Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype. [ Time Frame: 6 months ]
Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain. [ Time Frame: 6 months ]

Central Contacts and Locations

Central contacts

Christopher Beardmore

224 218 2408 chris@anovaevidence.com

Chloe Richmond

224 218 2408 chloe@anovaevidence.com

Locations

Precision NextGen Oncology

Recruiting

Beverly Hills, California, United States, 90212

Contacts

Francisco Capilla

(424) 777-0708 Franciscoc@nextgenonc.com

Principal Investigator:

Kamlesh Sankhala, MD

OPN Healthcare, Inc

Recruiting

Glendale, California, United States, 91203

Contacts

Heather Lyon

heatherl@opnhc.com

Principal Investigator:

Vu Phan, MD

University of Southern California

Recruiting

Los Angeles, California, United States, 90033

Contacts

Sandy Tran

(323) 865-3980 Sandy.Tran@med.usc.edu

Principal Investigator:

Frances Chow, MD

MDR Core Network

Recruiting

Boynton Beach, Florida, United States, 33426

Principal Investigator:

Robert Levin, MD

Vanderbilt University Medical Center

Recruiting

Nashville, Tennessee, United States, 37232

Principal Investigator:

Alexander Mohler, MD

Baylor, Scott and White Research Institute

Recruiting

Dallas, Texas, United States, 75246

Contacts

Tarah Satterfield

Tarah.Satterfield@bswhealth.org

Principal Investigator:

Divya Mella, MD

Northwest Medical Specialties

Recruiting

Tacoma, Washington, United States, 98405

Contacts

Sue Quinsey

253-380-8173

Principal Investigator:

Jorge Chaves, MD

More Information

Sponsor

Neonc Technologies, Inc.

Last update posted

Jul 16, 2026

Last verified

Jul, 2026

Keywords

Astrocytoma
IDH-mutant
Glioblastoma
IDH-wildtype
Brain Metastases
CNS Tumor
GBM
NeOnc
Anova
NEO212
NEO100
TMZ

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Neonc Technologies, Inc. on 2026-07-16.